Chronic wounds in aging populations represent a mounting healthcare challenge as traditional healing mechanisms become compromised by persistent inflammation and cellular dysfunction. The convergence of tissue engineering with traditional medicine offers potentially transformative approaches to address this growing clinical need.
Researchers developed a novel hydrogel system incorporating polysaccharides from Gastrodia elata—a medicinal mushroom—combined with glycyrrhizic acid, demonstrating the ability to fundamentally reprogram immune responses at wound sites. Testing in D-galactose-induced aging mouse models revealed the hydrogel actively shifts macrophages from inflammatory M1 phenotypes to healing-promoting M2 phenotypes over 21 days of treatment. The mechanism involves suppression of STAT3 phosphorylation pathways and reduction of pro-apoptotic Bax/Caspase-3 expression, effectively switching the local immune environment from destructive to regenerative.
This approach represents a significant departure from conventional wound care that primarily focuses on passive protection or antimicrobial effects. The dual-action strategy of providing structural support while actively modulating immune cell behavior addresses the root dysfunction in chronic wounds—dysregulated inflammation. The use of food-grade compounds enhances safety profiles compared to synthetic immunomodulators, potentially enabling longer treatment durations without systemic toxicity concerns. However, translation from mouse models to human applications remains unvalidated, and the complexity of human chronic wounds extends beyond the controlled aging model tested. The technology's true potential will depend on performance in diabetic ulcers, pressure sores, and other real-world chronic wound scenarios where multiple pathological processes intersect.